SEK2 (SAPK/ERK kinase 2), a key member of the mitogen-activated protein kinase kinase (MAPKK) family, plays a critical role in the cellular stress signal transduction network. By specifically activating downstream stress-activated protein kinases (SAPKs), it regulates cellular adaptive responses to various external signals such as oxidative stress, inflammatory stimuli, and DNA damage. In recent years, with advances in structural biology and cellular signal transduction research, the molecular mechanisms of SEK2 and its roles in physiological and pathological processes have gradually been revealed, providing important insights into understanding cellular stress regulatory networks and the pathogenesis of related diseases. This article systematically elaborates on the structural characteristics, signaling pathway regulation mechanisms of SEK2, and its biological significance in cellular functions and diseases.
SEK2 is a typical member of the MAPKK family, and the conservation of its domain composition and catalytic mechanism provides a molecular basis for its involvement in signal transduction.
The human SEK2 gene is located on chromosome 19p13.3 and encodes a protein consisting of 334 amino acid residues with a molecular weight of approximately 38 kDa. Its primary structure contains three core functional domains:
The N-terminal regulatory domain contains autoinhibitory sequences and phosphorylation sites for upstream kinases (such as Ser25 and Thr218), regulating kinase activity through conformational changes. The catalytic domain belongs to the serine/threonine kinase domain, containing an ATP-binding pocket (GxGxxG motif composed of Gly50-Gly55) and substrate recognition sites, where Asp156 acts as a catalytic base involved in phosphate group transfer. The C-terminal extension domain contains a nuclear localization signal (NLS) and protein interaction sequences, mediating the binding of SEK2 to downstream substrates or scaffold proteins and participating in the assembly of signal complexes.
Three-dimensional structural studies have shown that SEK2 exists in a "closed conformation" in the inactive state: the N-terminal regulatory domain interacts with the catalytic domain, masking the ATP-binding site. When activated by upstream signals, the regulatory domain is phosphorylated, leading to a conformational opening that exposes the catalytic center and enhances binding ability to substrates.
The catalytic activity of SEK2 depends on its own phosphorylation activation and specific recognition of downstream substrates:
In terms of activation mechanism, upstream kinases (such as MEKK1 and TAK1) phosphorylate the activation sites (Ser25 and Thr218) in the SEK2 catalytic domain, inducing conformational changes that expose the catalytic center and thereby activating kinase activity. For substrate recognition, SEK2 recognizes the activation loop sequence (TPY motif) of downstream SAPK family members (mainly JNK and p38α) through specific residues in the catalytic domain (such as Arg131 and Glu148), and achieves dual phosphorylation activation of substrates by transferring phosphate groups to Thr and Tyr residues. Reaction kinetics show that SEK2 has an affinity for ATP (Km value of approximately 2.5 μM) comparable to other MAPKK members, but its catalytic efficiency (kcat/Km) can be increased by 5-10 times through phosphorylation modification under stress conditions, ensuring rapid signal transmission.
As a key node in cellular stress signal transduction, SEK2 participates in the regulation of various physiological processes by integrating upstream stimulus signals and activating downstream effector molecules.
The activation of SEK2 is induced by various extracellular stimuli, and its upstream regulatory network is highly diverse and specific:
Among stress signals, oxidative stress (such as H₂O₂ treatment), ultraviolet irradiation, and osmotic pressure changes can directly phosphorylate the activation sites of SEK2 by activating the MEKK1-MEKK4 family kinases. In terms of inflammatory signals, inflammatory factors such as tumor necrosis factor (TNF-α) and interleukin-1 (IL-1) indirectly activate SEK2 through the Toll-like receptor (TLR)-TAK1 signaling axis. For metabolic signals, cellular energy stress (such as glucose deprivation) can enhance the interaction between SEK2 and downstream substrates through AMPK-mediated phosphorylation modification.
In addition, the activity of SEK2 is also finely regulated by post-translational modifications: ubiquitination (such as K48-linked ubiquitination mediated by SCF⁽β⁻ᵀᴿᶜᴾ⁾) promotes its proteasomal degradation, while SUMOylation (Lys165 site) enhances its retention and activity in the nucleus, forming a "activation-inactivation" dynamic balance.
SEK2 mainly transmits signals by activating JNK and p38 MAPK pathways, regulating cellular stress responses and fate determination:
In the JNK pathway, SEK2-mediated JNK phosphorylation activation can promote the nuclear translocation of transcription factor AP-1 (c-Jun/c-Fos), initiating the expression of pro-apoptotic genes (such as Bax and FasL) and participating in the regulation of cell apoptosis. In the p38 pathway, activated p38 induces the expression of inflammatory factors (such as IL-6 and TNF-α) and stress protection genes (such as HSP27) by phosphorylating transcription factors such as ATF2 and MEF2C, enhancing cellular adaptability to adverse environments. In terms of non-transcriptional regulation, SEK2 can also participate in cytoskeletal reorganization and cell migration by directly phosphorylating cytoplasmic proteins (such as microtubule-associated protein Tau).
This diversity of signal transduction enables SEK2 to initiate different cellular response programs according to the type and intensity of stimuli, reflecting the precision and flexibility of cellular stress regulation.
SEK2 plays an important role in maintaining body homeostasis and disease occurrence by regulating cellular stress responses, inflammatory reactions, and cell apoptosis.
In terms of cellular stress adaptation, under oxidative stress or DNA damage conditions, SEK2 induces the expression of HSPs by activating the p38 pathway, enhancing cellular antioxidant capacity and protein folding efficiency, and promoting cell survival. In immune inflammation regulation, in macrophages, SEK2-mediated JNK/p38 activation can promote lipopolysaccharide (LPS)-induced inflammatory factor secretion, participating in the initiation of innate immune responses. During tissue development, in the embryonic development stage, SEK2 affects the morphogenesis of the heart and nervous system by regulating the migration and differentiation of neural crest cells, and its functional deficiency can lead to embryonic lethality in mice.
Abnormal functions of SEK2 are closely related to the occurrence and development of various diseases:
In the field of tumors, in malignant tumors such as liver cancer and breast cancer, high expression of SEK2 can promote the anti-apoptotic ability and invasion and metastasis of tumor cells by activating the JNK pathway, and its expression level is negatively correlated with patient prognosis. In neurodegenerative diseases, Alzheimer's disease models show that SEK2-mediated excessive phosphorylation of Tau protein can promote the formation of neurofibrillary tangles and exacerbate neuronal damage. In inflammatory diseases, in synovial cells of patients with rheumatoid arthritis, abnormal activation of SEK2 can continuously induce inflammatory factor secretion by enhancing the activity of the p38 pathway, aggravating joint damage.
Recent studies have shown that SEK2 inhibitors (such as CC-401) can effectively reduce inflammatory reactions and tumor growth in animal models, suggesting their potential value as therapeutic targets for diseases.
With the innovation of technical means, SEK2 research is expanding from molecular mechanisms to clinical transformation, showing several directions worthy of attention:
In new discoveries in structural biology, cryo-electron microscopy has revealed the heterodimer structure formed by SEK2 and downstream JNK, and its interface interactions (such as Arg131 of SEK2 and Asp321 of JNK) provide a structural basis for designing specific inhibitors. Meanwhile, studies on the complex structure of SEK2 and scaffold proteins (such as JIP1) have revealed the molecular mechanism of spatial organization of signaling pathways.
In the regulatory network of post-translational modifications, in addition to phosphorylation, the regulatory effects of O-glycosylation (Ser12 site) and acetylation (Lys297 site) of SEK2 on its activity have gradually been discovered. These modifications may participate in the spatiotemporal regulation of stress signals by affecting its subcellular localization or protein interactions.
In the exploration of therapeutic applications, virtual screening based on the SEK2 structure has identified several new inhibitors, some of which have shown good anti-inflammatory and anti-tumor activities in animal models. At the same time, gene editing studies of SEK2 (such as CRISPR-Cas9-mediated knockout) provide a powerful tool for clarifying its causal relationship in diseases.
As a key kinase in cellular stress signal transduction, SEK2 plays an irreplaceable role in cellular adaptation, immune regulation, and tissue development by integrating upstream stimuli and activating downstream pathways. The analysis of its structural characteristics and catalytic mechanisms provides a molecular basis for understanding the organizational principles of the MAPK signaling network, and its close association with diseases highlights its potential value as a therapeutic target. Future research needs to further explore the functional specificity of SEK2 in different cell types, reveal its cross-regulatory mechanisms with other signaling pathways, and lay the foundation for developing precise SEK2-targeted disease treatment strategies.
Business license (three certificates in one) 